Madiha Derouazi

Direttore Tecnico/Scientifico/R&S presso AC IMMUNE SA

Patrimonio netto: 7 271 $ in data 30/04/2024

51 anni

Health Technology

Consumer Services

Relazioni attive

Nome	Sesso	Età	Società collegate	Collaborazione
Andrea Pfeifer	M	66	AC IMMUNE SA	21 anni
Douglas Williams	M	66	AC IMMUNE SA	6 anni
Oliver Sol	M	58	AC IMMUNE SA	8 anni
Gary Waanders	M	60	AC IMMUNE SA	-
Carl June	M	70	AC IMMUNE SA	4 anni
Werner Lanthaler	M	56	AC IMMUNE SA	6 anni
Jean-Fabien Monin	M	54	AC IMMUNE SA	15 anni
Christopher Roberts	M	35	AC IMMUNE SA	5 anni
Monika Bütler	M	63	AC IMMUNE SA	3 anni
Piergiorgio Donati	M	54	AC IMMUNE SA	6 anni
Roy Ervin Twyman	M	68	AC IMMUNE SA	5 anni
Monica Shaw	M	46	AC IMMUNE SA	3 anni
Johanna Holldack	M	-	Amal Therapeutics SA Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.	-
Howard Donovan	M	49	AC IMMUNE SA	2 anni
Julian Snow	M	-	AC IMMUNE SA	-
Mark Danton	M	60	AC IMMUNE SA	5 anni
Andreas Wallnöfer	M	63	Amal Therapeutics SA Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.	-
Bojana Portmann	M	43	AC IMMUNE SA	13 anni
Julien Rongère	M	47	AC IMMUNE SA	7 anni
Alexandre Caratsch	M	59	AC IMMUNE SA	6 anni
Frank Kalkbrenner	M	-	Amal Therapeutics SA Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.	-
Sonia Maria Poli	M	59	AC IMMUNE SA	7 anni
Karin Hehenberger	M	52	Amal Therapeutics SA Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.	-
Nuno Mendonça	M	42	AC IMMUNE SA	1 anni

Mostra altro

Grafico relazionale

Relazione in diverse aziende

Relazioni precedenti

Nome	Sesso	Età	Società collegate	Collaborazione
Marie Kosco-Vilbois	M	67	AC IMMUNE SA	5 anni
Roberto de Ponti	M	-	Amal Therapeutics SA Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.	1 anni
Laurence de Schoulepnikoff	F	-	Amal Therapeutics SA Amal Therapeutics SA BiotechnologyHealth Technology Amal Therapeutics SA engages in the development of peptide-based therapeutic cancer vaccines. It offers KISMA, a novel peptide/protein-based immunization technology platform, which is self-adjuvanting and enables the assembly within one chimeric fusion protein of elements essential to generate potent immunity. The company was founded by Madiha Derouazi on September 3, 2012 and is headquartered in Geneva, Switzerland.	-

Statistiche

Paese	Relazioni	% del totale
Svizzera	27	100.00%

Età delle relazioni

Attive

Scorse

Uomo

Donna

Amministratori

Dirigenti

Provenienza delle relazioni